Neurosense Therapeutics Ltd. (NRSN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NeuroSense Therapeutics has announced promising results from its PARADIGM study, showing that its drug PrimeC significantly slows disease progression and boosts survival rates in ALS patients. The study suggests a 33% improvement in disease progression and a 58% increase in survival rates for those starting treatment with PrimeC, potentially redefining ALS care standards.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.